WooGene B&G Co., Ltd

KOSDAQ:A018620 Stock Report

Market Cap: ₩26.1b

WooGene B&G Past Earnings Performance

Past criteria checks 2/6

WooGene B&G has been growing earnings at an average annual rate of 31.9%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 12.7% per year. WooGene B&G's return on equity is 2.2%, and it has net margins of 2.1%.

Key information

31.9%

Earnings growth rate

32.6%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate12.7%
Return on equity2.2%
Net Margin2.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

Dec 17
These 4 Measures Indicate That WooGene B&G (KOSDAQ:018620) Is Using Debt Extensively

WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

Aug 06
WooGene B&G Co., Ltd's (KOSDAQ:018620) Share Price Could Signal Some Risk

WooGene B&G (KOSDAQ:018620) Takes On Some Risk With Its Use Of Debt

Apr 06
WooGene B&G (KOSDAQ:018620) Takes On Some Risk With Its Use Of Debt

A Look At WooGene B&G's (KOSDAQ:018620) Share Price Returns

Feb 12
A Look At WooGene B&G's (KOSDAQ:018620) Share Price Returns

Would WooGene B&G (KOSDAQ:018620) Be Better Off With Less Debt?

Dec 21
Would WooGene B&G (KOSDAQ:018620) Be Better Off With Less Debt?

Revenue & Expenses Breakdown

How WooGene B&G makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A018620 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2458,6401,24112,8181,009
30 Jun 2459,95916712,0011,028
31 Mar 2460,624-68811,3531,056
31 Dec 2357,919-1,18410,821907
30 Sep 2349,120-98,821683
30 Jun 2347,8028948,309474
31 Mar 2344,8781797,595336
31 Dec 2243,7038506,661270
30 Sep 2247,578-1,3516,756289
30 Jun 2245,964-1,4466,359284
31 Mar 2241,535-8286,319327
31 Dec 2139,347-2,2586,427305
30 Sep 2134,790-3,5505,732248
30 Jun 2134,516-2,0825,901201
31 Mar 2138,287-4,2436,154148
31 Dec 2039,524-3,0306,246105
30 Sep 2042,980-2,2246,67098
30 Jun 2040,141-2,9256,30242
31 Mar 2036,154-5225,87015
31 Dec 1929,656-3335,56059
30 Sep 1927,2113495,557110
30 Jun 1927,524-1,6025,599104
31 Mar 1928,208-4,8435,616116
31 Dec 1828,131-6,6325,766106
31 Dec 1722,934-4,1906,866513

Quality Earnings: A018620 has a large one-off loss of ₩337.0M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A018620 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A018620 has become profitable over the past 5 years, growing earnings by 31.9% per year.

Accelerating Growth: A018620 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A018620 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).


Return on Equity

High ROE: A018620's Return on Equity (2.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 07:31
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WooGene B&G Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution